Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation

BACKGROUND: Costimulatory blockade provides new therapeutic opportunities for ensuring the long-term survival of kidney grafts. The adoption of the novel immunosuppressant Belatacept has been limited, partly due to concerns regarding higher rates and grades of acute rejection in clinical trials. In...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Zhang, Hengcheng, Wang, Zijie, Zhang, Jiayi, Gui, Zeping, Han, Zhijian, Tao, Jun, Chen, Hao, Sun, Li, Fei, Shuang, Yang, Haiwei, Tan, Ruoyun, Chandraker, Anil, Gu, Min
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7959759/
https://ncbi.nlm.nih.gov/pubmed/33732243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.618737
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados